Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer
The phenomenology, clinical consequences, and underlying mechanisms of cytochrome P450 and drug transporter regulation by inflammatory and infectious stimuli, and the consequences of inflammatory cytokine production by tumors for drug safety and efficacy in cancer patients were outlined.
Regulation of drug metabolism and disposition during inflammation and infection
- K. Renton
- Biology, MedicineExpert Opinion on Drug Metabolism & Toxicology
- 30 November 2005
For any drug that is metabolised by CYP and has a narrow therapeutic index, there is a significant risk in placing patients in a position where an infection or inflammatory response might lead to aberrant drug handling and an adverse drug response.
Alteration of drug biotransformation and elimination during infection and inflammation.
- K. Renton
- BiologyPharmacology and Therapeutics
- 1 November 2001
Cytochrome P450 regulation and drug biotransformation during inflammation and infection.
- K. Renton
- BiologyCurrent drug metabolism
- 31 May 2004
In clinical medicine there are numerous examples of a decreased capacity to handle drugs during infections and disease states that involve an inflammatory component, which often results in altered drug responses and increased toxicities.
Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin
- K. Goralski, G. Hartmann, M. Piquette-Miller, K. Renton
- Biology, MedicineBritish Journal of Pharmacology
- 1 May 2003
The major finding was that the CNS inflammation in male rats produced a loss in the expression of mdr1a mRNA in the brain and liver that was maximal 6 h after intracranial ventricle (i.c.v.) administration of LPS.
Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human.
- R. McLellan, R. Drobitch, M. Monshouwer, K. Renton
- Biology, MedicineDrug Metabolism And Disposition
- 1 October 1996
These studies in hepatic microsomes demonstrate that fluoroquinolones can decrease CYP3A- and CYP1A-mediated biotransformation by competitive inhibition and that they have the potential to cause drug interactions with agents metabolized by these enzymes.
Cytokine-mediated down-regulation of CYP1A1 in Hepa1 cells.
Proton-coupled oligopeptide transporter (POT) family expression in human nasal epithelium and their drug transport potential.
The uptake, permeation, qPCR/RT-PCR and protein expression data showed that the human nasal epithelium functionally expresses proton-coupled oligopeptide transporters.
Depression of hepatic cytochrome P-450-dependent monooxygenase systems with administered interferon inducing agents.
Effects of polyribonoinosinic acid polyribocytidylic acid and a mouse interferon preparation on cytochrome P-450-dependent monooxygenase systems in cultures of primary mouse hepatocytes.
Poly rI·rC was shown to induce interferon activity in cultured hepatocytes and mouse interferons induced the hydroxylase activity in 24-hr-old cultures of hepatocytes, and aminopyrine N-demethylase and benzo[a]pyrene hydroxyase activities were determined.